TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: [11C]Acetate PET in Patients With Glioma

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Male or female, age 18 and older, of any ethnic group~* Spanish-speaking patients will be eligible~* Histological diagnosis of glioma or~* Brain MR imaging suggestive of a glioma or 2HG \> 2mM by MR spectroscopy in patients who have not had a surgical procedure to establish the diagnosis.~* Karnofsky Performance status \> 70%~* Negative serum pregnancy test or child bearing potential terminated by surgery, radiation, menopause or current use of two approved methods of birth control~* Patient able and willing to provide informed consent~Exclusion Criteria:~* Patient or legal parent/guardian unable to provide informed consent~* Psychiatric or addictive disorders that preclude obtaining informed consent~* Karnofsky Performance status \< 70%~* NYHA class III and IV congestive heart failure~* Unstable angina~* Pregnant or lactating women~* Women of childbearing potential who refuse a pregnancy test

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- [11C]Acetate Brain Imaging (Type: EXPERIMENTAL): \[11C\]Acetate will be administered The patient will have one intravenous line placed prior to \[11C\]Acetate administration. The patient will receive the low-dose CT portion of a PET/CT scan, after which \[11C\]Acetate will be administered intravenously over approximately 1 min at a dose of 0.3 mCi/kg (maximum 30 mCi) and followed by a saline flush. The injection and imaging procedure will be terminated in any patient who exhibits anaphylaxis, significant dyspnea or chest pain. The administering physician will stay with the patient for at least 15 min after injection and will remain in the Clinical PET Facility through the duration of the imaging procedure.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Data Registry Following Patients Using Supera Stent in the Femoral Arteries

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Exclusion Criteria:~(Clinical)~* Patient or legal guardian understands registry procedures and has voluntarily signed an informed consent in accordance with institutional and local regulatory policies. (Note: Retrospective data may be collected and entered into the EDC system after a fully executed informed consent has been provided).~* Rutherford-Becker classification 2 through 5 only~* Patient is at least 18 years of age and of legal age of consent.~* Patient must be willing to participate in the registry for at least 5 years.~(Angiographic)~* Target lesion is a single de novo or restenotic (outside a stent) SFA or Popliteal artery lesion ≥ 1 cm from origin of another stent; additional lesions may be present., but there is only one target lesion~* All SFA target lesions are to be located with the proximal point at least 2 cm below the origin of the profunda femoris artery.~* All Popliteal Artery target lesions are to be located with the most distal point at least 1 cm proximal to the bifurcation of the anterior tibial artery and the tibioperoneal trunk.~* Target lesion length 1-20 cm (visual estimate)~* Target lesion stenosis ≥50% (visual estimate)~* Popliteal artery patent if the lesion is in the SFA~* SFA patent if the lesion is in the popliteal artery~* At least one widely patent (\< 50% stenosis) infrapopliteal artery (for distal run-off)~Exclusion Criteria:~(Clinical)~* Evidence of heparin induced thrombocytopenia (HIT), or intravenous tPA, Plavix, Ticlid, or aspirin therapy sensitivities~* Patient is participating in a clinical study that could confound results~* Patient is pregnant/breastfeeding at time enrollment or plans to become pregnant during the course of participation in the registry.~(Angiographic)~* Target lesion length \> 20 cm~* Instent restenotic / reoccluded target lesion~* Acute (≤ 4 weeks) thrombotic occlusion~* Untreated ipsilateral pelvic stenosis

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Device SUPERA Stent (Type: OTHER): SUPERA Interwoven Self-Expanding Nitinol Stent System

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Basket Trial in Solid Tumors Harboring a Fusion of FGFR1, FGFR2 or FGFR3- (FUZE Clinical Trial)

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Cytologically or histologically confirmed advanced solid tumor~* Radiographic progression on prior systemic therapy; prior localized therapy (i.e., radiation, ablation, embolization) is allowed provided radiographic progression out-of-field or in the treatment, field is shown~* Locally-advanced (unresectable) or metastatic disease harboring an FGFR1-3 gene fusion/rearrangement potentially leading to a functional FGFR aberrant protein, identified through local and/or central molecular assay~Exclusion Criteria:~* History of hypersensitivity to any of the excipients in the Debio 1347 formulation~* History and/or current evidence of ectopic mineralization/calcification, including but not limited to soft tissue, kidneys, intestine, myocardia, or lung, excepting calcified lymph nodes, lung nodules and asymptomatic vascular or cartilage/tendon calcifications~* Administration of any investigational agent within 2 weeks prior to initial dosing with Debio 1347 (3 weeks for immune checkpoint inhibitors)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Cohort 1: Debio 1347 (Biliary Tract Cancer) (Type: EXPERIMENTAL): Participants with biliary tract cancer were included in this cohort to receive Debio 1347 80 milligrams (mg) tablets, orally, once daily (QD), from Day 1 to Day 28 in 28-day cycles until the occurrence of disease progression or unacceptable toxicity (up to a median duration of 20 weeks).
- Cohort 2: Debio 1347 (Urothelial Cancer) (Type: EXPERIMENTAL): Participants with urothelial cancer were included in this cohort to receive Debio 1347 80 mg tablets, orally, QD, from Day 1 to Day 28 in 28-day cycles until the occurrence of disease progression or unacceptable toxicity (up to a median duration of 5.86 weeks).
- Cohort 3: Debio 1347 (All Other Solid Tumor Histologies) (Type: EXPERIMENTAL): Participants with all other solid tumor histologies were included in this cohort to receive Debio 1347 80 mg tablets, orally, QD, from Day 1 to Day 28 in 28-day cycles until the occurrence of disease progression or unacceptable toxicity (up to a median duration of 8.14 weeks).

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: MUltiple Sclerosis and Extract of Cannabis (MUSEC) Study

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Signed informed consent.~* Diagnosis of MS according to McDonald criteria.~* Current muscle stiffness ≥ 4 on a 11-point categorical rating scale.~* On-going troublesome muscle stiffness for at least 3 months.~* Stable disease for the previous 6 months.~* Antispasticity medication and physiotherapy stabilised for the last 30 days.~* Patients may be ambulatory or not.~* Age 18-64.~Exclusion Criteria:~* Immunosuppressants which may affect spasticity (including corticosteroids and interferon but ex-cluding azathioprine) taken currently or in previous 30 days~* Past or present history of psychotic illness.~* Open/infected pressure sores or other source of chronic infection.~* Significant fixed tendon contractures.~* Severe cognitive impairment such that the patient is unable to provide informed consent.~* History of clinically important renal, cardiovascular or neurol. diseases (apart from MS).~* Malignancy within the past 2 years.~* Cannabinoids taken currently or in previous 30 days.~* Positive qualitative urinary test on cannabinoids at screening visit. (In this case a patient will be allowed to repeat the test at a second screening visit later.)~* Known hypersensitivity to cannabinoids.~* Current drug abuse, including alcohol abuse.~* Laboratory parameters outside the following limits:~Creatinine \> 3x upper limit of normal Bilirubine \> 3x upper limit of normal Transaminases \> 5 x upper limit of normal~* Anticipated immunisations within the 12 weeks of trial participation.~* Other problems likely to make participation difficult at the discretion of the neurologist.~* Women who are pregnant, lactating or not using adequate contraception.~* Participation in other treatment studies currently or within the previous month.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 64 Years
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): Cannabis extract (delta-9-THC 2.5mg, CBD 1.25 mg per capsule), flexible dosing between 5 mg and 25 mg THC/d, administered twice daily
- 2 (Type: PLACEBO_COMPARATOR): matching placebo capsules, twice daily

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Proof of Concept Trial of Gleevec (Imatinib) in Active Diffuse Scleroderma

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Subjects must be able to give informed consent.~* Subjects must meet preliminary criteria for scleroderma.~* Subjects must have diffuse skin involvement.~* Disease must appear to be active as measured by worsening skin score and/or increased ESR.~* Serum SGOT \< 1.5 times upper limit of normal.~* Bilirubin \< 1.5 times upper limit of normal.~* AST/ALT \< 2.5 times upper limit of normal~Exclusion Criteria:~* Any past exposure to Gleevec.~* Women of child bearing potential must be practicing an acceptable form of contraception (OCP, depo-provera, IUD, condoms with spermicidal or sterilization of subject or partner).~* Women who are breastfeeding.~* Men whose partners could conceive must be practicing acceptable contraception (see above).~* Certain abnormal labs including: Neutrophil count \<1.5X109/L, platelets \< 50X109/L.~* Serious comorbidity that may impair the ability to complete the study (such as severe heart disease, severe pulmonary hypertension) and other comorbidities.~* Prednisone at doses of \>10mg/od.~* Other potential disease modifying drugs such as cyclophosphamide, mycophenylate and methotrexate.~* Serious liver disease.~* Creatinine \>200.~* Excluded: Ketoconazole and fluconazole, cyclosporine, rifampin, phenytoin nefazodone, pimozide, propafenone, quinidine, sibutramine and sildenafil where drug interactions could occur.~* Subjects taking endothelin receptor blockers such as bosentan and sitaxsentan.~* Alcohol consumption of \> 3 drinks per week.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Gleevec (Type: EXPERIMENTAL): Gleevec 200 mg bid for 6 months.
- Placebo (Type: PLACEBO_COMPARATOR): Placebo coated to appear identical to Gleevec.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: safety issues
Please assess the completion status of the following clinical trial:

Trial Title: Non-Invasive Characterization in Cardiac Sarcoidosis

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. 18 years of age or older~2. must have undergone a cardiac positron emission tomography (PET) scan using 18F-fluorodeoxyglucose (FDG) for clinical reasons (i.e. referred by your doctor) within the preceding 30 days which showed evidence of active inflammation in your heart.~Exclusion Criteria:~1. If you have two copies of a genetic variation called rs6971 which will prevent this tracer from generating high-quality images you may not participate. If you consent, a blood sample will be drawn to check whether you have this genetic variation.~2. Pregnancy or breastfeeding. If you are female and still experience menstrual periods, you must be willing to use contraception until your participation in the study is complete.~3. Allergy or intolerance to contrast dye containing gadolinium~4. Claustrophobia which would prevent you from completing an approximately one hour MRI scan~5. Inability to lie flat with your arms by your head~6. Abnormal kidney function (estimated GFR(glomerular filtration rate) \<60 ml/min/1.73 m2)~7. Implanted pacemaker, defibrillator or other medical devices which are not safe for 3 Tesla MRI~8. Metal in the eyes or shrapnel in the body~9. If you are clinically unstable you may not participate in this study. For example, if you have potentially life threatening abnormal heart rhythms which are not controlled by medication or other treatments, you cannot participate. Also, if you need medications to increase your blood pressure or cardiac function due to weak heart muscle, you cannot participate.~   -

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 11C-PBR PET (Type: EXPERIMENTAL): Subjects will have a blood sample drawn to evaluate the presence of a specific genetic variation which would prevent the new type of imaging test we are evaluating from working and we will test the inflammatory cells in the blood for the same purpose.~All participants who proceed will have to return on at least one additional day to undergo a positron emission tomography (PET) scan similar to the scan your doctor ordered. we will use 11C-PBR28 as the radiotracer. This study will evaluate whether 11C-PBR28 can show areas of inflammation due to cardiac sarcoidosis. On either the same day or a different day, you will also undergo a cardiac MRI.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Testing New Method of Analyzing MR Images

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Females~* Age 18 years or greater~* Undergoing breast MRI exam~Exclusion Criteria:~* Pregnancy~* Contraindication for MRI on standard screening checklist for clinically indicated examinations (i.e. metal devices/implants; history of claustrophobia)~* History/presence of any of the following to the breast: injury; breast implant; surgical or interventional procedure; clinically significant abnormality

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Study of Immunotoxin, MR1-1

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Residual, progressive, or recurrent supratentorial malignant brain tumor based on imaging studies with measurable disease (\>0.5cm).~* Patient will have completed some form of radiation therapy prior to toxin treatment.~* Karnofsky Performance score \>70.~* The presence of the target antigen, EGFRvIII, must be identified on tumor tissue by immunohistochemistry.~* Platelet count \> 100 x 109/L; PTT and PT \< 120% of normal range.~* Creatinine \< 120% of normal range.~* Total bilirubin, SGOT, SGPT,alkaline phosphatase \< 300% of normal range.~Exclusion Criteria:~* Patients who are pregnant, breast-feeding, or unwilling to practice an effective method of birth control.~* Patients with known potentially anaphylactic allergic reactions to iodine or gadolinium-DTPA.~* Patients who cannot undergo MRI due to obesity or to having certain metal in their bodies (specifically pacemakers, infusion pumps, metal aneurysm clips, metal prostheses, joints, rods or plates).~* Patients that have not recovered from the toxic effects of prior chemotherapy and/or radiation therapy.~* Patients with an impending, life-threatening cerebral herniation syndrome.~* Patients with subependymal or CSF disease.~* Patients who are under the age of 18 years.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- MR1-1 (Type: EXPERIMENTAL): All subjects are enrolled onto this arm. All subjects will receive MR1-1.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Child HCAHPS: Automated Day of Discharge Survey

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: HEALTH_SERVICES_RESEARCH
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Their child's hospitalization includes at least one overnight stay~Exclusion Criteria:~* Their child is aged 18 or older during the hospitalization~* Their child is hospitalized with a primary psychiatric diagnosis~* Their child dies during hospitalization~* Their child is in the hospital as a court/law enforcement patient~* Their child is a ward of the state~* Their child was admitted under DCF jurisdiction~* They are not fluent in English or Spanish

- Gender: ALL
- Minimum Age: None
- Maximum Age: 17 Years
- Healthy Volunteers: t

Study Arms:
- Child HCAHPS: Automated Administration (Type: EXPERIMENTAL): Child HCAHPS: Automated day-of-discharge survey~On the day of discharge at the hospital, parents will be contacted to solicit survey responses using patient televisions (GetWell) as follows:~Day 0 (Day of likely discharge): Respondent will be promoted to complete Child HCAHPS on their television as part of the routine discharge process. Respondent will also be asked for their email address to complete post-discharge items and their appropriate contact information will be collected.~Days 2-42: Standard hospital protocol (i.e., mail, email, or IVR) with the post-discharge questions.
- Standard Administration of Child HCAHPS (Type: NO_INTERVENTION): Parents will be contacted to complete Child HCAHPS using the standard protocol for mail, email, or IVR survey administration. The surveys will be administered by the survey vendor contracted by the participating site to administer Child HCAHPS.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Dexmedetomidine for Postoperative Sedation in Patients Undergoing Repair of Thoracoabdominal Aortic Aneurysms

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* All Patients over age 18 undergoing non-emergent repair of type I-III TAA~Exclusion Criteria:~* Pregnancy~* Patients with hepatic impairment (increase of ALT or AST three times normal)~* Patient taking clonidine or tricyclic antidepressants.~* Patients taking opioids or benzodiazepines chronically (\> 2 doses a day for \> 1 month)~* Patients with second or third degree heart block without a pacer~* Patients undergoing emergency repair of TAA~* Intraoperative cardiac arrest~* Intraoperative massive blood loss (\>10 l)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- 1 (Type: PLACEBO_COMPARATOR): Normal Saline
- Dexmedetomidine (Type: ACTIVE_COMPARATOR): Dexmedetomidine is a highly specific a2 agonist with prominent central nervous system and cardiovascular effects. A postoperative sedative-hypnotic agent for intensive care patients for use up to 24 hours.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: Scandinavian Intensive Care Unit (ICU) Glutamine Study

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* admission to the ICU~* decision to give the patient full nutrition~* APACHE II score \> 10 at admission~* age 18-85 years~Exclusion Criteria:~* readmission to the ICU after a previous ICU-stay in which the patient has been included into the study~* subjects with any condition which in the opinion of the attending physician makes the subject unsuitable for inclusion~* no informed consent

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 85 Years
- Healthy Volunteers: f

Study Arms:
- Glutamine (Type: EXPERIMENTAL): Intravenous glutamine supplementation (0.285 g/kg body weight/24 h)
- Control (Type: PLACEBO_COMPARATOR): saline

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues